leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 00:39:00 - browse：3

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Robert F. Kennedy is pitching centrism on health, even on abortion

focus

WSS

Medicare Advantage proposed rates disappoint insurers

To avoid data mishandling cases, universities eye AI and other tools

Leukemia patients are helped by Syndax's new type of therapy

FDA needs staff influx to meet gene therapy needs, Marks says

Medicare Advantage proposed rates disappoint insurers

SCOTUS to consider access to abortion pill mifepristone

hotspot

leisure time

leisure time

Medical records are filled with copy

For Medicare Advantage, Democrats want stronger protections around AI

As demand for Covid shots wanes, Moderna seeks its next success

Industry veterans launch new biotech VC with $310M

Peter Hotez and the public health issue of online harassment

Patients' immediate access to test results puts radiologists in a bind

Peter Hotez and the public health issue of online harassment

KalVista pill reduced swelling 'attacks' caused by genetic disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare Advantage proposed rates disappoint insurers

leisure time

Pharma patents targeted by Biden in move to slash drug prices

Pregnancy discrimination could be enabled by AI

Doctors' information doesn't help them choose wisely when sick

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Senators start work on Medicare physician payment reform

Medicare threatens to cut off funding for HCA's Mission hospital

hotspot

focus

Wikipedia

focus